Mechanisms of apoptosis induction and cell cycle regulation in irradiated leukemia U937 cells and enhancement by arsenic trioxide

Radiation Research

Volumn 165, Issue 4, 2006, Pages 390-399

  Ho, Sheng Yow ^a,b   Huang, Po Chang ^a,b   Guo, How Ran ^a   Chang, Wen Huei ^c   Chen, Rong Jane ^a   Wei, Bai Lu ^d   Wu, Wei Jr ^a   Tai, Chein ^a   Wang, Ying Jan ^a,e  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b TAINAN SIN LAU HOSPITAL   (Taiwan)

^c CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^d NATIONAL TAITUNG UNIVERSITY   (Taiwan)

^e NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; CYCLIN A; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; DNA;

APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CELL CYCLE; CONTROLLED STUDY; DNA DAMAGE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IRRADIATION; LEUKEMIA CELL; PRIORITY JOURNAL; RADIATION DOSE; WESTERN BLOTTING;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; ARSENICALS; CELL CYCLE; CELL CYCLE PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; OXIDES; RADIATION DOSAGE; RADIATION TOLERANCE; U937 CELLS;

EID: 33645464728     PISSN: 00337587     EISSN: None     Source Type: Journal    
DOI: 10.1667/RR3518.1     Document Type: Article

References (55)

1. N. H. Nam and K. Parang, Current targets for anticancer drug discovery. Curr. Drug Targets 4, 159-179 (2003).
2. T. J. McDonnell, R. E. Meyn and L. E. Robertson, Implications of apoptotic cell death regulation in cancer therapy. Semin. Cancer Biol. 6, 53-60 (1995).
3. K. Shinohara and H. Nakano, Interphase death and reproductive death in X-irradiated MOLT-4 cells. Radiat. Res. 135, 197-205 (1993).
4. I. R. Radford, Mouse lymphoma cells that undergo interphase death show markedly increased sensitivity to radiation-induced DNA double-strand breakage as compared with cells that undergo mitotic death. Int. J. Radiat. Biol. 59, 1353-1369 (1991).
5. T. Yamada and H. Ohyama, Radiation-induced interphase death of rat thymocytes is internally programmed (apoptosis). Int. J. Radiat. Biol. 53, 65-75 (1988).
6. N. Shinomiya, Y. Kuno, F. Yamamoto, M. Fukasawa, A. Okumura, M. Uefuji and M. Rokutanda, Different mechanisms between premitotic apoptosis and postmitotic apoptosis in X-irradiated U937 cells. Int. J. Radiat. Oncol. Biol. Phys. 47, 767-777 (2000).
7. R. E. Shackelford, W. K. Kaufmann and R. S. Paules, Cell cycle control, checkpoint mechanisms, and genotoxic stress. Environ. Health. Perspect. 107 (Suppl. 1), 5-24 (1999).
8. D. R. Aldridge and I. R. Radford, Explaining differences in sensitivity to killing by ionizing radiation between human lymphoid cell lines. Cancer Res. 58, 2817-2824 (1998).
9. L. N. Su and J. B. Little, Prolonged cell cycle delay in radioresistant human cell lines transfected with activated ras oncogene and/or simian virus 40 T-antigen. Radiat. Res. 133, 73-79 (1993).
10. R. G. Syljuasen and W. H. McBride, Radiation-induced apoptosis and cell cycle progression in Jurkat T cells. Radiat. Res. 152, 328-331 (1999).
11. K. H. Antman, Introduction: The history of arsenic trioxide in cancer therapy. Oncologist 6 (Suppl. 2), 1-2 (2001).
12. Y. Shen, Z. X. Shen, H. Yan, J. Chen, X. Y. Zeng, J. M. Li, X. S. Li, W. Wu, S. M. Xiong and Z. Chen, Studies on the clinical efficacy and pharmacokinetics of low-dose arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia: A comparison with conventional dosage. Leukemia 15, 735-741 (2001).
13. S. L. Soignet, Clinical experience of arsenic trioxide in relapsed acute promyelocytic leukemia. Oncologist 6 (Suppl. 2), 11-16 (2001).
14. R. Uslu, U. A. Sanli, C. Sezgin, B. Karabulut, E. Terzioglu, S. B. Omay and E. Goker, Arsenic trioxide-mediated cytotoxicity and apoptosis in prostate and ovarian carcinoma cell lines. Clin. Cancer Res. 6, 4957-4964 (2000).
15. Z. Y. Shen, J. Shen, W. J. Cai, C. Hong and M. H. Zheng, The alteration of mitochondria is an early event of arsenic trioxide-induced apoptosis in esophageal carcinoma cells. Int. J. Mol. Med. 5, 155-158 (2000).
16. 3) in the orthotopic metastasis model of androgen-independent prostate cancer. Cancer Res. 61, 5432-5440 (2001).
17. C. Huang, W. Y. Ma, J. Li and Z. Dong, Arsenic induces apoptosis through a c-Jun NH2-terminal kinase-dependent, p53-independent pathway. Cancer Res. 59, 3053-3058 (1999).
18. Z. Dong, The molecular mechanisms of arsenic-induced cell transformation and apoptosis. Environ. Health Perspect. 110 (Suppl. 5), 757-759 (2002).
19. +-dependent production of superoxide. Int. J. Cancer 92, 518-526 (2001).
20. 2/M growth arrest and apoptosis after caspase-3 activation and bcl-2 phosphorylation in promonocytic U937 cells. Biochem. Biophys. Res. Commun. 286, 726-734 (2001).
21. 3). FEBS Lett. 519, 195-200 (2002).
22. K. L. Hopcia, Y. L. McCarey, F. C. Sylvester and K. D. Held, Radiation-induced apoptosis in HL60 cells: Oxygen effect, relationship between apoptosis and loss of clonogenicity, and dependence of time to apoptosis on radiation dose. Radiat. Res. 145, 315-323 (1996).
23. D. O. Morgan, Principles of CDK regulation. Nature 374, 131-134 (1995).
24. 1 cyclin-dependent kinases. Genes Dev. 9, 1149-1163 (1995).
25. I. R. Radford and D. R. Aldridge, Importance of DNA damage in the induction of apoptosis by ionizing radiation: Effect of the scid mutation and DNA ploidy on the radiosensitivity of murine lymphoid cell lines. Int. J. Radiat. Biol. 75, 143-153 (1999).
26. Z. H. Siddik, B. Mims, G. Lozano and G. Thai, Independent pathways of p53 induction by cisplatin and X-rays in a cisplatin-resistant ovarian tumor cell line. Cancer Res. 58, 698-703 (1998).
27. B. Zhivotovsky, B. Joseph and S. Orrenius, Tumor radiosensitivity and apoptosis. Exp. Cell. Res. 248, 10-17 (1999).
28. R. E. Meyn, Apoptosis and response to radiation: Implications for radiation therapy. Oncology (Huntingt.) 11, 349-356 (1997).
29. S. J. Kuerbitz, B. S. Plunkett, W. V. Walsh and M. B. Kastan, Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. USA 89, 7491-7495 (1992).
30. 1/S-phase and late S-phase checkpoints with regulation of cyclin-dependent kinases in Chinese hamster ovary cells. Radiat. Res. 148, 260-271 (1997).
31. 2 checkpoint in p53-independent apoptosis induction by X-irradiation. Mol. Cell. Biol. 15, 5849-5857 (1995).
32. A. S. Hendrikse, A. J. Hunter, M. Keraan and G. H. Blekkenhorst, Effects of low dose irradiation on TK6 and U937 cells: Induction of p53 and its role in cell-cycle delay and the adaptive response. Int. J. Radiat. Biol. 76, 11-21 (2000).
33. S. Fan, W. S. el-Deiry, I. Bae, J. Freeman, D. Jondle, K. Bhatia, A. J. Fornace, Jr., I. Magrath, K. W. Kohn and P. M. O'Connor, p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res. 54, 5824-5830 (1994).
34. W. S. el-Deiry, p21/p53, cellular growth control and genomic integrity. Curr. Top. Microbiol. Immunol. 227, 121-137 (1998).
35. Z. N. Oltvai, C. L. Milliman and S. J. Korsmeyer, Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74, 609-619 (1993).
36. 3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood 88, 1052-1061 (1996).
37. Y. Akao, H. Mizoguchi, S. Kojima, T. Naoe, N. Ohishi and K. Yagi, Arsenic induces apoptosis in B-cell leukaemic cell lines in vitro: Activation of caspases and down-regulation of Bcl-2 protein. Br. J. Haematol. 102, 1055-1060 (1998).
38. G. Filomeni, G. Rotilio and M. R. Ciriolo, Glutathione disulfide induces apoptosis in U937 cells by a redox-mediated p38 MAP kinase pathway. FASEB J. 17, 64-66 (2003).
39. F. Brockhaus and B. Brune, U937 apoptotic cell death by nitric oxide: Bcl-2 downregulation and caspase activation. Exp. Cell Res. 238, 33-41 (1998).
40. L. Shi, W. K. Nishioka, J. Th'ng, E. M. Bradbury, D. W. Litchfield and A. H. Greenberg, Premature p34cdc2 activation required for apoptosis. Science 263, 1143-1145 (1994).
41. S. C. Shen, T. S. Huang, S. H. Jee and M. L. Kuo, Taxol-induced p34cdc2 kinase activation and apoptosis inhibited by 12-O-tetrade-canoylphorbol-13- acetate in human breast MCF-7 carcinoma cells. Cell. Growth Differ. 9, 23-29 (1998).
42. Y. H. Ling, U. Consoli, C. Tornos, M. Andreeff and R. Perez-Soler, Accumulation of cyclin B1, activation of cyclin B1-dependent kinase and induction of programmed cell death in human epidermoid carcinoma KB cells treated with Taxol. Int. J. Cancer 75, 925-932 (1998).
43. S. L. Yao, K. A. McKenna, S. J. Sharkis and A. Bedi, Requirement of p34cdc2 kinase for apoptosis mediated by the Fas/APO-1 receptor and interleukin 1beta-converting enzyme-related proteases. Cancer Res. 56, 4551-4555 (1996).
44. T. Shimizu, P. M. O'Connor, K. W. Kohn and Y. Pommier, Unscheduled activation of cyclin B1/Cdc2 kinase in human promyelocytic leukemia cell line HL60 cells undergoing apoptosis induced by DNA damage. Cancer Res. 55, 228-231 (1995).
45. K. S. Choi, Y. W. Eom, Y. Kang, M. J. Ha, H. Rhee, J. W. Yoon and S. J. Kim, Cdc2 and Cdk2 kinase activated by transforming growth factor-beta1 trigger apoptosis through the phosphorylation of retinoblastoma protein in FaO hepatoma cells. J. Biol. Chem. 274, 31775-31783 (1999).
46. 2 block induced by ionizing radiation. Cancer Res. 51, 5113-5117 (1991).
47. 2 blocks, cyclin B expression and cdc2 expression in human squamous carcinoma cell lines with different radiosensitivities. Radiother. Oncol. 33, 217-227 (1994).
48. S. Wang, M. G. Hasham, I. Isordia-Salas, A. Y. Tsygankov, R. W. Colman and Y. L. Guo, Upregulation of Cdc2 and cyclin A during apoptosis of endothelial cells induced by cleaved high-molecular-weight kininogen. Am. J. Physiol. Heart Circ. Physiol. 284, H1917-H1923 (2003).
49. L. Shi, G. Chen, D. He, D. G. Bosc, D. W. Litchfield and A. H. Greenberg, Granzyme B induces apoptosis and cyclin A-associated cyclin-dependent kinase activity in all stages of the cell cycle. J. Immunol. 157, 2381-2385 (1996).
50. J. Yi, F. Gao, G. Shi, H. Li, Z. Wang, X. Shi and X. Tang, The inherent cellular level of reactive oxygen species: One of the mechanisms determining apoptotic susceptibility of leukemic cells to arsenic trioxide. Apoptosis 7, 209-215 (2002).
51. M. Enari, R. V. Talanian, W. W. Wong and S. Nagata, Sequential activation of ICE-like and CPP32-like proteases during Fas-mediated apoptosis. Nature 380, 723-726 (1996).
52. H. Sakahira, M. Enari and S. Nagata, Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis. Nature 391, 96-99 (1998).
53. X. Sheng-Tanner, E. A. Bump and D. W. Hedley, An oxidative stress-mediated death pathway in irradiated human leukemia cells mapped using multilaser flow cytometry. Radiat. Res. 150, 636-647 (1998).
54. 3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 89, 3354-3360 (1997).
55. Y. Shen, Z. X. Shen, H. Yan, J. Chen, X. Y. Zeng, J. M. Li, X. S. Li, W. Wu, S. M. Xiong and Z. Chen, Studies on the clinical efficacy and pharmacokinetics of low-dose arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia: a comparison with conventional dosage. Leukemia 15, 735-741 (2001).